Evidence map›Paper›PMID 31329864›Full record

Trial reportDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2019

Heartburn and dyspepsia symptom severity improves after treatment and correlates with histology in adults with eosinophilic esophagitis.

Swathi Eluri, Irina Perjar, Renee Betancourt, Cara Randall, Soha Raja, John T Woosley, Nicholas J Shaheen, Evan S Dellon

Abstract readClinical Trial
In one paragraph

Trial report in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Early life factors are associated with risk for eosinophilic esophagitis diagnosed in adulthood.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Swathi EluriCenter for Esophageal Diseases and Swallowing.
Irina PerjarDepartment of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, North Carolina, USA.
Renee BetancourtDepartment of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, North Carolina, USA.
Cara RandallDepartment of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, North Carolina, USA.
Soha RajaCenter for Esophageal Diseases and Swallowing.
John T WoosleyDepartment of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, North Carolina, USA.
Nicholas J ShaheenCenter for Esophageal Diseases and Swallowing.
Evan S DellonCenter for Esophageal Diseases and Swallowing.

Funding

PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Temitope O. Keku · 1985 to 2026
$30.5M
DIGESTIVE DISEASES EPIDEMIOLOGY TRAINING PROGRAMT32DK007634 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1990 to 2026
$7.4M
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative TherapyK24DK100548 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHAHEEN, NICHOLAS J · 2013 to 2017
$896k
Risk Factors and Biomarkers for Diagnosis & Treatment of Eosinophilic EsophagitisK23DK090073 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DELLON, EVAN SAMUEL · 2011 to 2013
$541k
NIDDK NIH HHS K23 DK090073NIDDK NIH HHS K24 DK100548NIDDK NIH HHS P30 DK034987NIDDK NIH HHS T32 DK007634
6 · The paper itself

Abstract

Non-dysphagia symptoms, such as heartburn and dyspepsia, are poorly characterized in adults with eosinophilic esophagitis (EoE). It is unclear if treatment improves these symptoms. The aim of this paper was to assess (i) heartburn and dyspepsia symptom severity in adult EoE patients using validated symptom measures; (ii) change in symptoms after treatment; and (iii) symptom association with endoscopic and histologic features. In a prospective cohort of adult EoE patients who were not responsive to proton pump inhibitor therapy, non-dysphagia symptoms were assessed with heartburn items from the validated GERD-HRQL (gastroesophageal reflux disease health-related quality of life) and SODA (severity of dyspepsia assessment) instruments. Subjects completed the questionnaires at baseline and after treatment. Association of baseline symptoms with endoscopic and histologic features, and before and after treatment with diet or topical steroids, was assessed. Eighty-six EoE patients (mean age 39 years, 57% male, 95% white) completed a baseline questionnaire and 62 completed the follow-up questionnaire. The mean baseline GERD-HRQL score was 4.5 ± 6.5 and the mean total SODA score was 41.0 ± 12.6. At baseline, there was a weak but significant correlation between peak eosinophils and the SODA score (r = 0.28; p = 0.03) and no association between heartburn and SODA scores and endoscopic or other histologic findings. After treatment, there was a decrease in GERD-HRQL heartburn (4.3 vs. 2.6; p = 0.04) and SODA (49.5 vs. 35.5; p = 0.04) scores in histologic responders, but not in nonresponders. In a prospective cohort of EoE patients, baseline eosinophils positively correlated with dyspepsia severity. Heartburn and dyspepsia symptoms improved after treatment in histologic responders.

Indexed as

Diet TherapySeverity of Illness IndexAdultAnti-Inflammatory AgentsBudesonideCombined Modality TherapyDyspepsiaEosinophilic EsophagitisEsophagoscopyFemaleFluticasoneFollow-Up StudiesHeartburnHumansMaleMiddle AgedAnti-Inflammatory AgentsBudesonideFluticasonedyspepsiaeosinophilic esophagitisheartburnsymptom

Identifiers

PMID31329864
PMCPMC7608739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.